Literature DB >> 22520400

Human C-reactive protein accentuates macrophage activity in biobreeding diabetic rats.

Ishwarlal Jialal1, Harmeet Kaur, Sridevi Devaraj.   

Abstract

OBJECTIVE: Type 1 diabetes (T1DM) is a pro-inflammatory state characterized by high C-reactive protein (CRP) levels. However, there is a paucity of data examining the role of CRP in promoting the pro-inflammatory state of diabetes. Thus, we examined the pro-inflammatory effects of human CRP using spontaneously diabetic bio-breeding (BB) rats.
METHODS: Diabetic rats (n=9/group) were injected with Human serum albumin (huSA) or Human CRP (hCRP, 20 mg/kg body weight; i.p.) for 3 consecutive days. Blood and peritoneal macrophages (MØ) were obtained following euthanasia. Peritoneal macrophages were used for measuring superoxide anion release, NF-κB DNA binding activity, proinflammatory mediator secretion.
RESULTS: hCRP administration resulted in significantly increased superoxide anion production, along with increased release of cytokines/chemokines, and plasminogen activator inhibitor (PAI-1) and Tissue Factor (TF) activity in diabetic rats compared to huSA. hCRP-treated BB rat MØ showed significant induction of protein kinase C (PKC)-alpha, PKC-delta and p47 phox expression and NF-κB compared to huSA.
CONCLUSIONS: Thus, our data suggest that human CRP exacerbates in-vivo the pro-inflammatory, pro-oxidant and procoagulant states of diabetes predominantly via increased macrophage activity and this could have implications with respect to vascular complications and anti-inflammatory therapies. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22520400      PMCID: PMC3404262          DOI: 10.1016/j.jdiacomp.2012.03.020

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  61 in total

Review 1.  Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis.

Authors:  Subodh Verma; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Circulation       Date:  2006-05-02       Impact factor: 29.690

2.  Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction.

Authors:  M Romano; M Pomilio; S Vigneri; A Falco; P L Chiesa; F Chiarelli; G Davì
Journal:  Diabetes Care       Date:  2001-09       Impact factor: 19.112

Review 3.  C-reactive protein and cardiovascular disease: new insights from an old molecule.

Authors:  G M Hirschfield; M B Pepys
Journal:  QJM       Date:  2003-11

4.  C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

Authors:  Sridevi Devaraj; Dan Yan Xu; Ishwarlal Jialal
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

5.  Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha.

Authors:  Senthil Kumar Venugopal; Sridevi Devaraj; Teddy Yang; Ishwarlal Jialal
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

6.  C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification.

Authors:  Helen M Colhoun; Casper Schalkwijk; Michael B Rubens; Coen D A Stehouwer
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

7.  Effect of C-reactive protein on chemokine expression in human aortic endothelial cells.

Authors:  Sridevi Devaraj; Pappanaicken R Kumaresan; Ishwarlal Jialal
Journal:  J Mol Cell Cardiol       Date:  2004-03       Impact factor: 5.000

8.  Lifetime risk for diabetes mellitus in the United States.

Authors:  K M Venkat Narayan; James P Boyle; Theodore J Thompson; Stephen W Sorensen; David F Williamson
Journal:  JAMA       Date:  2003-10-08       Impact factor: 56.272

9.  C-reactive protein and incident cardiovascular events among men with diabetes.

Authors:  Matthias B Schulze; Eric B Rimm; Tricia Li; Nader Rifai; Meir J Stampfer; Frank B Hu
Journal:  Diabetes Care       Date:  2004-04       Impact factor: 19.112

10.  Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein.

Authors:  Seiichi Kobayashi; Nobutaka Inoue; Yoshitaka Ohashi; Mitsuyoshi Terashima; Kiyoko Matsui; Takao Mori; Hideki Fujita; Kojiro Awano; Katsuya Kobayashi; Hiroshi Azumi; Junya Ejiri; Ken-ichi Hirata; Seinosuke Kawashima; Yoshitake Hayashi; Hiroshi Yokozaki; Hiroshi Itoh; Mitsuhiro Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-12       Impact factor: 8.311

View more
  5 in total

1.  Antisense to protein kinase C-alpha and p47phox attenuates the pro-inflammatory effects of human C-reactive protein in macrophages of biobreeding diabetic rats.

Authors:  Ishwarlal Jialal; Sridevi Devaraj
Journal:  Diab Vasc Dis Res       Date:  2012-07-16       Impact factor: 3.291

Review 2.  Redox-Sensitive Innate Immune Pathways During Macrophage Activation in Type 1 Diabetes.

Authors:  Ashley R Burg; Hubert M Tse
Journal:  Antioxid Redox Signal       Date:  2017-11-27       Impact factor: 8.401

3.  Prenatal dexamethasone exposure in rats results in long-term epigenetic histone modifications and tumour necrosis factor-α production decrease.

Authors:  Hong-Ren Yu; Ho-Chang Kuo; Chih-Cheng Chen; Jiunn-Ming Sheen; Mao-Meng Tiao; Yu-Chieh Chen; Kow-Aung Chang; You-Lin Tain; Li-Tung Huang
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

Review 4.  Current siRNA targets in atherosclerosis and aortic aneurysm.

Authors:  Leena Pradhan-Nabzdyk; Chenyu Huang; Frank W LoGerfo; Christoph S Nabzdyk
Journal:  Discov Med       Date:  2014-05       Impact factor: 2.970

Review 5.  Macrophages in oxidative stress and models to evaluate the antioxidant function of dietary natural compounds.

Authors:  Omir Adrian Castaneda; Sheng-Chi Lee; Chi-Tang Ho; Tzou-Chi Huang
Journal:  J Food Drug Anal       Date:  2016-12-07       Impact factor: 6.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.